Novartis CAR-T cell therapy Kymriah is approved by Health Canada for 2 B-cell malignancies

, the CAR-T cell therapy Kymriah (CTL019), developed by SwissPharmaceutical(http://giant Novartis, has been approved by Health Canada for 2 Types of B-cell malignancies :(1) B-cell acute lymphoblastic leukemia (B-ALL) children and young adults aged 3-25 years; The approval marks the beginning of a new era of cancer treatment, making Kymriah the first CAR-T cell therapy approved in Canada, Novartis is currently in talks with cancer care in Ontario, Canada, and after reaching an agreement, Kymriah will provide to young B-ALL patients who have adifficult condition to treat or who have received an allogeneic stem cell transplant (SCT) or who do not meet SCT, or have had two or more relapses;(2) adult patients with recurrent or refractory large B-cell lymphoma (R/R LBCL) who have previously received 2 or more systemic therapies, including diffuse large B-cell lymphoma (DLBCL), plifying lactator lymphoma (FL) and high-level B-cell lymphoma and DLBCLso far, two CAR-T cell therapies have been approved for the market: Novartis's Kymriah and Gilead's YescartaUnlike conventional small molecule sorority or biotherapy, it is a live T-cell therapyproduct(http://Kymriah and Yescarta are both genetically modified and genetically modified of the patient's T cells to express a chimeric antigen receptor (CAR) designed to target antigen CD19, an antigen protein that is expressed on the surface of a variety of blood tumor cells, including B-cell lymphoma and leukemia cells